Larimar Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 42
- Market Cap
- $514.2M
- Website
- http://larimartx.com
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06681766
- Locations
- 🇺🇸
Uncommon Cures, Chevy Chase, Maryland, United States
An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia
Phase 2
- Conditions
- Friedreich Ataxia
- Interventions
- Biological: CTI-1601
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06447025
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida, United States
🇺🇸Fixel Institute for Neurological Disease, University of Florida Health, Gainesville, Florida, United States
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05579691
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
Completed
- Conditions
- Friedreich AtaxiaHealthy Volunteers
- Interventions
- Diagnostic Test: Buccal Swabs, Blood Draws and Skin Punch Biopsy
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05028764
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Phase 1
Completed
- Conditions
- Friedreich Ataxia
- Interventions
- Biological: PlaceboBiological: CTI-1601
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04519567
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia
Completed
- Conditions
- Friedreich Ataxia
- Interventions
- Diagnostic Test: Buccal Swabs and Blood Draws
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04255680
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Phase 1
Completed
- Conditions
- Friedreich Ataxia
- Interventions
- Biological: PlaceboBiological: CTI-1601
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04176991
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath